Search results
Showing 7471 to 7485 of 7674 results
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
New clot-busting drug recommended by NICE set to save NHS £millions
Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
NICE recommends digital technology to help diagnose ADHD in children and young people
A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
More than 700 people set to benefit from new treatment option for advanced lymphoma.
Draft guidance for the potential of new targeted treatment for type of advanced breast cancer
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
NICE publishes final draft guidance on Enhertu after commercial discussions conclude
NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.
New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..